HMMJ-U:CA:TSX-Horizons Marijuana Life Sciences Index ETF (USD)

ETF | Others |

Last Closing

CAD 7.6

Change

0.00 (0.00)%

Market Cap

CAD 0.09B

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

+0.25 (+0.92%)

CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

N/A

CAD 4.83B
PHYS-U:CA Sprott Physical Gold Trust

+0.23 (+1.27%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

+0.25 (+0.36%)

CAD 4.54B
HXT-U:CA Horizons S&P/TSX 60 Index ETF

N/A

CAD 3.92B
XEQT:CA iShares Core Equity Portfolio

+0.24 (+0.78%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

+0.47 (+2.12%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

N/A

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.03 (-0.14%)

CAD 2.78B
NUBF:CA NBI Unconstrained Fixed Income..

N/A

CAD 2.52B

ETFs Containing HMMJ-U:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.73% 67% D+ 64% D
Dividend Return 1.09% 71% C- 38% F
Total Return 9.82% 69% C- 63% D
Trailing 12 Months  
Capital Gain 18.38% 73% C 73% C
Dividend Return 1.19% 62% D 27% F
Total Return 19.57% 75% C 73% C
Trailing 5 Years  
Capital Gain -45.56% 2% F 12% F
Dividend Return 0.55% 17% F 3% F
Total Return -45.01% 2% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain 17.52% 97% N/A 85% B
Dividend Return 17.52% 97% N/A 84% B
Total Return 0.00% 10% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 63.69% 3% F 12% F
Risk Adjusted Return 27.51% 59% D- 52% F
Market Capitalization 0.09B 63% D 36% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.